Available Technologies
# of Displayed Technologies: 2 / 2
Novel Therapy for Treating Sarcopenia and Nerve Injury
TS-037778 —
A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia
Muscle weakness (sarcopenia) affects more than 5% of those over 60. It is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and function, leading to impaired mobility, slow gait, decreased quality of life, and death. Healthcare costs associated with mus…
- College: College of Medicine (COM)
- Inventors: Burghes, Arthur; Arnold, William; Kaspar, Brian; McGovern, Vicki
- Licensing Officer: He, Panqing
Antisense Oligonucleotide Development for Treatment of Spinal Muscular Atrophy
TS-037741 —
The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.
Spinal muscular atrophy (SMA) is an inherited disease affecting the central nervous system, peripheral nervous system, and skeletal muscle. It is present primarily in infants and children but can also develop in adults. About 10,000 to 25,000 children and adults are living with the disease in the …
- College: College of Medicine (COM)
- Inventors: Burghes, Arthur; McGovern, Vicki; Prior, Thomas
- Licensing Officer: He, Panqing
